The clinical-stage company Verseon (Fremont, California) is unique among companies exploring the use of AI in drug discovery given its focus on what it calls the “uncharted” chemical space. While Big Pharma companies typically test compounds from their collections for specific diseases, these collections often have constraints and overlapping compounds. Adityo Prakash, CEO of Verseon,…
BenevolentAI is pioneering AI-driven drug discovery methods
“Can we treat chronic inflammation in ulcerative colitis by reversing immune cell activation in colonic mucosa?” That’s an example of a biological question that the AI-enabled drug discovery firm BenevolentAI (AMS:BAI) would ask when exploring a new drug target. Incorporating a disease, sign, mechanism and tissue into a single question provides focal points for the…
Using AlphaFold, Insilico Medicine produces AI drug discovery in record time
Capitalizing on AI drug discovery, an international group of researchers employed DeepMind’s deep learning-driven AlphaFold protein structure database to swiftly design and synthesize a potential hepatocellular carcinoma (HCC) drug in only 30 days. The AI drug discovery project consisted of Insilico Medicine, the University of Toronto’s Acceleration Consortium and researchers including Nobel laureate Michael Levitt.…